News | June 12, 2007

Newer Contrast Agents Safe for Children

June 13, 2007 – According to a recent study conducted by researchers from the University of Michigan Medical Center and C.S. Mott Children’s Hospital both in Ann Arbor, MI, allergic-like reactions to newer iodine-containing contrast agents (nonionic contrast media), are rare in children.

“Over the past 20 years, we have changed the type of iodine-containing intravenous contrast agents used primarily for computed tomography (CT) and intravenous pyelogram (IVP) examinations in both adult and pediatric patients. The nonionic contrast media that we now use have been studied extensively in adults, but not as much in children. We performed our study because we wanted to find out what the exact risk of allergic reactions to these newer contrast agents was in children,” said Jonathan R. Dillman, MD, lead author of the study.

The study evaluated 11,306 pediatric IV administrations of iodine-containing contrast agents over a seven year period. According to the study, acute allergic-like reactions were documented in 20 of the patients. Of these patients, 16 of the allergic-like reactions were categorized as mild, one as moderate, and three as severe. Six of the reacting patients had a history of allergic-like reactions, including two patients who had a history of reactions to iodinated contrast material. Five of the patients had a history of asthma.

For more information: www.med.umich.edu

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init